Food interaction of oral uptake of iron: A clinical trial using 59Fe

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 6 A, 2007, Pages 401-416

  Lundqvist, Hans ^a   Sjöberg, Folke ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Berzelius Science Park   (Sweden)

Author keywords

Antianemic drugs; Iron deficiency; Iron uptake, food interaction; Iron(III) hydroxide; Maltofer ; Polymaltose complex

Indexed keywords

IRON 59; IRON POLYMALTOSE; MALTOFER; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMOGRAPHY; DIARRHEA; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; ERYTHROCYTE; FEMALE; FOOD DRUG INTERACTION; HEMATOLOGICAL PARAMETERS; HUMAN; IRON DEFICIENCY; IRON TRANSPORT; MALE; ORANGE JUICE; RADIOACTIVITY; SINGLE DRUG DOSE; VITAL SIGN;

EID: 34447330724     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296689     Document Type: Article

References (24)

1. Iron deficiency anaemia: assessment, prevention and control. A guide for programme managers. Geneva: World Health Organization; 2001 (Document WHO/NHD/01.3). http://www.who.int/nut/documents/ida_assessment_preven tion_control.pdf
2. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittel-Forschung (Drug Research). 1992;42:1439-1452.
3. Geisser P In vitro studies on interactions of iron salts and complexes with food-stuffs and medicaments. Arzneimittel-Forschung (Drug Research). 1990;40:754-760.
4. Johnson G, Jacobs P. Bioavailability and the mechanism of intestinal absorption of iron from ferrous ascorbate and ferric polymaltose in experimental animals. Exp Hematol. 1990;18:1064-1069.
5. Tuomainen T, Nyyssönen K, Porkkala-Sarataho E, Salonen R, Baumgartner JA, Geisser P, et al. Oral supplementation with ferrous sulphate but not with non-ionic iron polymaltose complex increases the susceptibility of plasma lipoproteins to oxidation. Nutr Res. 1999;19:1121-1132.
6. Langstaff RJ, Geisser P, Heil WG, Bowdler JM. Treatment of iron-deficiency anaemia: a lower incidence of adverse effects with Ferrum Hausmann than ferrous sulphate. Brit J Clin Res. 1993;4:191-198.
7. Kaltwasser JP, Werner E, Niechzial M. Bioavailability and therapeutic efficacy of bivalent and triavlent iron preparations. Arzneimittel-Forschung (Drug Research). 1987;37:122-129.
8. Jacobs P, Fransman D, Coghlan P. Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron-deficient blood-donors. J Clin Apheresis. 1993;8:89-95.
9. Sas G, Nemesanszky E, Bräuer H, Scheffer K. On the therapeutic effects of trivalent and divalent iron in iron deficiency anaemia. Arzneimittel-Forschung (Drug Research). 1984; 34:1575-1579.
10. Jacobs P, Wood L, Bird AR. Better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology. 2000;5:77-83.
11. Schmidt BJ, Morais MB, Fisberg M, Martins A, Machado N. Comparação terapêutica entre o sulfato ferroso e o ferro trivalente em forma de complexo dehidróxido férrico polimaltosado na deficiência orgânica de ferro. Fol Med. 1985;90:225-229.
12. Grandjean EM. Scientific report on the clinical safety of the iron(III)-hydroxide polymaltose complex (Maltofer®) [internal report]. St. Gallen (Switzerland): Vifor (International) Inc.; 1997.
13. Mackintosh W, Jacobs P. Response in serum ferritin and haemoglobin to iron therapy in blood donors. Am J Hematol. 1988;27:17-19.
14. Jacobs P, Johnson G, Wood L. Oral iron therapy in human subjects. Comparative absorption between ferrous salts and iron polymaltose. J Med. 1984;15:367-377.
15. Murahovschi J, Stein ML, Careffa RC, De Andrade VL, Da Compos Guerra CC, Falci M. Tratamento da ferropenia e da anemia ferropenica com o complexo de hidroxido de ferro polimaltosado por via oral, de crianças em fase de recuperaçao de infecçoes respiratorias. Ensaio duplo-cego, comparative com sulfato ferroso. Rev Paul Ped. 1987;5:97.
16. D'Amico E, Mazzoni P, Castangna PC. Impiego di un preparato di ferro polimaltosato per via orale nell'anemia ferropriva del bambino. Med Praxis. 1986;7:1-12.
17. Picchini F, Di Pietro M, Di Battista S, Moretti P, Celommi ML, Natali L, et al. Contributo clinico sull'uso di un preparato orale a base di ferro polimaltosato (Intrafer). Minerv Ped. 1987;39:729-733.
18. 12 [internal report]. St. Gallen (Switzerland): Vifor (International) Inc.; 1978.
19. Periodic Safety Update Report. Maltofer® (Iron(III)-hydroxide polymaltose complex) for oral use [internal report]. St. Gallen (Switzerland): Vifor (International) Inc.; 2005.
20. Jacobs P, Wormald LA, Gregory MC. Absorption of iron polymaltose and ferrous sulphate in rats and humans. S Afr Med J. 1979;55:1065-1072.
21. Makin A. Iron polymaltose complex: toxicity to dogs by repeated oral administration for 52 weeks [internal report]. St. Gallen (Switzerland): Vifor (International) Inc.; 1998.
22. Schaub E, Chovan K, Bürgin M, Renker H, Müller A. Gastrointestinal tolerance of iron haematinics on rabbits. Hausmann Laboratories, 20 Sep 1984.
23. Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51:224-232.
24. Aggett P. Iron and women in the reproductive years. In: The Report of the British Nutrition Foundation Task Force, ed. Iron Nutritional and Physiological Significance. Chapman and Hall; 1995. p. 110-118.